GlobeNewswire Inc.··NaGalapagos, Gilead in Advanced Talks on T-Cell Therapy Partnership
Galapagos and Gilead are in advanced partnership talks for a first-in-class T-cell engager for autoimmune diseases, with 50% cost-sharing and €500 million capital freed for Galapagos.
GILDGLPGstrategic partnershipclinical development